KBC Securities - MDXHEALTH (MDXH) mdxhealth FIRST LOOK: FY24 highlights unlock path to EBITDA profitability

Report

KBC Securities

Thomas Vranken

mdxhealth FIRST LOOK: FY24 highlights unlock path to EBITDA profitability

mdxhealth provides insight into key FY24 parameters, with revenues landing at $ 90m (KBCSe: $ 88.5m) and YE cash at $ 46.8m (KBCSe: $ 47.1m. Revenue guidance for FY25 is set at a narrow yet ambitious range of $ 108-110m, implying a 20-22% y/y increase. We believe that mdxhealth is well-positioned for growth in 2025 now that the commercial engine is firing on all cylinders, hence we maintain our $ 4.2 TP and Buy rating.

13/01/2025 1 EN

Underlying

MDXHEALTH

See profile

BE0974461940 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

KBC Securities

mdxhealth 3Q25 results continue adj. EBITDA profitability, guidance maintained

Yesterday evening mdxhealth reported 3Q25 results. The company had $ 27.4m in revenue up 18% y/y, with a gross margin of 65.2% representing a 4% improvement. OPEX was essentially flat leading to a second quarter of adj. EBITDA profitability of $ 1m. The company reiterated its FY25 revenue guidance and reported that it will fully focus on integrating the ExoDx acquisition into the business in the 4Q25. Therefore, it will postpone Germline and re-evaluate the opportunity in 2026. We reiterate our BUY rating and $ 4.2 TP.

November 13, 2025 November 13, 2025 1 EN

KBC Securities

Morning Notes : AGN NA, AGFB BB, IVA FP, MDXH BB, MELE BB, SOLB BB, DEME BB, AUTL US, ZEAL DC, PHVS US

: AGN NA, AGFB BB, IVA FP, MDXH BB, MELE BB, SOLB BB, DEME BB, AUTL US, ZEAL DC, PHVS US

November 13, 2025 November 13, 2025 1 EN

GlobeNewsWire

Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025

Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 Q3 revenues increased by 18% to $27.4 millionAdjusted EBITDA profitability of $1.0 million for Q3Acquisition of ExoDx business from Bio-Techne CorporationConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA – November 12, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the three and ...

November 12, 2025 November 12, 2025 1 EN

Morning Notes : SEQUA BB

: SEQUA BB

5h / 9m 5h / 9m 1 EN

Mathijs Geerts Danau

Mathijs Geerts Danau

Sequana Medical New DSR patent improves value of program

Sequana announces granting of a key additional methods and formulation patent for DSR. This patent increases durability and expands protection of Sequana's DSR IP, thereby improving its value. We note that the patent provides additional time for Sequana to secure dedicated financing to advance DSR toward the randomized controlled portion of the MOJAVE clinical study. We reiterate our BUY rating.

5h / 15m 5h / 15m 1 EN

Michiel Declercq

Michiel Declercq

Colruyt 1H25/26 disappoints, outlook reiterated, but with caution

Although Colruyt already flagged during the AGM that the operating result in 1H25/26 would be lower, the -15.8% EBIT decline in 1H25/26 to € 213m came in below our estimates (kbcse: € 230m). While Colruyt still banks on a stable operating result and net profit for FY25/26, the group did highlight that the situation has become more complicated following the ongoing price and promo pressure, increased Sunday openings, abolition of the mandatory closing day and uneven level playing field in labour costs. As we believe it will be no easy task to achieve the outlook, we lower our TP from €41 to €38...

21h / 43m 21h / 43m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

mdxhealth FIRST LOOK: FY24 highlights unlock path to EBITDA profitability

We are a financial services provider for several types of professional clients, each with distinct needs.

mdxhealth 3Q25 results continue adj. EBITDA profitability, guidance maintained

Morning Notes : AGN NA, AGFB BB, IVA FP, MDXH BB, MELE BB, SOLB BB, DEME BB, AUTL US, ZEAL DC, PHVS US

Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025

Morning Notes : SEQUA BB

Sequana Medical New DSR patent improves value of program

Colruyt 1H25/26 disappoints, outlook reiterated, but with caution

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe